Open Access<p>Patient Preferences Associated with Anti-Vascular Endothelial Growth Factor Therapies for Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema</p>
Author(s) -
Davis Bhagat,
Breanne Kirby,
Harit Bhatt,
Rama D. Jager,
Mark S. George,
Veeral Sheth
Publication year - 2020
Publication title -
clinical ophthalmology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.025
H-Index - 56
eISSN - 1177-5483
pISSN - 1177-5467
DOI - 10.2147/opth.s273564
Subject(s) - medicine , macular degeneration , diabetic macular edema , ophthalmology , ranibizumab , preference , cohort , bevacizumab , diabetes mellitus , diabetic retinopathy , chemotherapy , microeconomics , economics , endocrinology
To evaluate treatment-related preferences among patients receiving intravitreal anti-vascular endothelial growth factor (VEGF) therapy for neovascular age-related macular degeneration (nAMD) or diabetic macular edema (DME).